Immune checkpoint blockade (ICB) therapy targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 was tolerated with manageable toxicities and promising antitumor effect in patients with GC (Aggelis et al., 2018). This evidence concerns the gene PDCD1 and gastric cancer.